Please login to the form below

Not currently logged in
Email:
Password:

Pharma growth in emerging markets nearly double global average

While US growth slows to 2.6 per cent, according to GlobalData report

BRIC - Brazil Russia India China flags

Major pharma firms reported an increased growth rate in emerging economies  during 2011 of 13.4 per cent, nearly double that of the global average of 7.8 per cent, according to a new report.

Pharmaceutical Leaders 2012, an analysis of the top 25 pharma companies by GlobalData, also revealed slow US growth of just 2.6 per cent, emphasising the industry's increasing move from traditionally strong markets to emerging countries, including the BRIC nations – Brazil, Russia, India and China.

This is due to rising incomes, expanding access to healthcare and the subsidised nature of central planning governments in emerging nations, according to the report, while traditional markets are being hit by patent losses and austerity measures.

It's a trend that's set to continue too, with a report published earlier this month by IMS suggesting that over the next five years, emerging economies will expand by around 10 percentage points to reach 30 per cent of global spending.

This has been reflected already in such moves as GlaxoSmithKline's (GSK) recruitment drive for sales reps in China that followed job cuts in both the US and Europe.

Big pharma's decline in traditional markets is paving the way for the generic industry, however, according to GlobalData's report, with the top five generic companies reporting global revenues of $31bn during 2011, an increase of 11.3 per cent from the previous years.

This has been fuelled by the lost of patent protection for big-selling drugs, such as Pfizer's Lipitor (atorvastatin) and Eli Lilly's Zyprexa (olanzapine).

Healthcare cuts, particularly in countries hit hardest by the economic crisis, are also making the European market increasingly unstable for larger pharma companies, with hospitals in Greece, Spain and Portugal all facing suspended drug sales over unpaid bills.

In addition, R&D budgets have been cut significantly, with the industry narrowing its focus to develop medications most likely to be commercial successful, according to GlobalData.

26th July 2012

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Halesway

A Eureka moment! A converted dairy in the Hampshire countryside back in 1993 saw the inception of Halesway as a...

Latest intelligence

access denied
Sales reps struggle to access doctors
Doctors continue to turn away from face-to-face visits from pharma sales reps and look instead towards mobile technology for information...
Online Physician Communities
Research finds doctors are optimistic about new diabetes drugs but concerned over rationing
New data from M3 Global Research shows that clinicians buy in to the effectiveness of new diabetes therapies. However, they are concerned about rationing and believe that more resources are...
McCann.jpg
The heart of the matter: Part Two
How is social media impacting publication planning?...